- Home
- YJ vs MBRX Comparison
YJ vs MBRX Comparison
Compare YJ & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YJ | MBRX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.6M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | YJ | MBRX |
|---|---|---|
| Price | $1.49 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 4.3K | ★ 621.4K |
| Earning Date | 03-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,760,127.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $3.63 |
| 52 Week High | $2.67 | $91.25 |
Technical Indicators
Market Signals| Indicator | YJ | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 51.12 |
| Support Level | $1.41 | $3.74 |
| Resistance Level | $1.69 | $4.24 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 6.67 | 5.40 |
Price Performance
Historical ComparisonAbout YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.